omniture

Tianyin to Attend Rodman & Renshaw 2010 Annual Global Investment Conference at New York from September 12 - September 15

2010-09-09 07:49 1458

CHENGDU, China, Sept. 9 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a biopharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics will participate in the Rodman & Renshaw 2010 Annual Global Investment Conference at the New York Palace Hotel from September 12 till September 15, 2010.

Presenter: Dr. James Jiayuan Tong,

Title: Chief Financial Officer, Chief Business & Development Officer, Director

Presentation time: 9:10 am September 15

Location: Kennedy I Salon (4th floor), New York Palace.

About Tianyin Pharmaceuticals

Tianyin Pharmaceutical Co., Inc., headquartered at Chengdu, China, is a biopharmaceutical company that specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicines and branded generics. Tianyin currently manufactures a comprehensive portfolio of 56 products, of which 23 are listed in the national medicine reimbursement list, 7 are included in the essential drug list of China. Tianyin currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

     James Jiayuan Tong M.D. Ph.D.
     Chief Financial Officer, Chief Business & Development Officer
     Director
     Tianyin Pharmaceutical Co., Inc.
     Web:     http://www.tianyinpharma.com
     Email:   Dr.Tong@tianyinpharma.com
     Tel:     +86-28-8551-6696 (Chengdu, China)
              +86-134-3655-0011 (China)
              +1-949-350-6999 (U.S.)
     Address: 23rd Floor Unionsun Yangkuo Plaza
              No 2 Block 3 South Renmin Road
              Chengdu, 610041
              China


Source: Tianyin Pharmaceutical Co., Inc.
Related Stocks:
NYSE:TPI
collection